Drugs / PCO371
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04649216 | Nov → Dec 2020 | — | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04209179 | Jul → Dec 2020 | hypoparathyroidism | Chugai Pharmaceutical | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02475616 | Jun → Oct 2015 | — | Chugai Pharmaceutical | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCO371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02475616 ↗ |
| Known as | Pc-0371 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3976807 ↗ |
| Modality | Small molecule | — CHEMBL3976807 ↗ |
| Route | Oral | “single oral (PO) administration of PCO371” NCT02475616 ↗ |